GHRS Stock Forecast: GH Research Plc Price Predictions for 2026-2027
The 10 Wall Street analysts covering GH Research Plc hold a median 12-month price target of $40 — +128.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 62 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores GH Research Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (78): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Growth (27): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
GHRS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on GHRS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +128.2% from it.
Of the 20 most recent actions, 5 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Nov 2026 | Guggenheim | Maintains | Buy | $40 → $46 |
| 17 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $65 → $55 |
| 7 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | $35 → $40 |
| 7 Aug 2026 | Guggenheim | Maintains | Buy | $34 → $40 |
| 6 Aug 2026 | Needham | Maintains | Buy | $32 → $39 |
| 27 July 2026 | Wells Fargo | Initiates | Overweight | $44 |
| 19 May 2026 | HC Wainwright & Co. | Maintains | Buy | $70 → $65 |
| 15 May 2026 | Cantor Fitzgerald | Maintains | Overweight | $25 → $35 |
| 15 May 2026 | Citizens | Maintains | Market Outperform | $42 → $39 |
| 6 Mar 2026 | Citizens | Maintains | Market Outperform | — |
| 6 Mar 2026 | Needham | Maintains | Buy | — |
| 2 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 23 Jan 2026 | RBC Capital | Maintains | Outperform | — |
| 6 Jan 2026 | Canaccord Genuity | Maintains | Buy | — |
| 6 Jan 2026 | Needham | Maintains | Buy | — |
| 5 Jan 2026 | Needham | Reiterates | Buy | — |
| 10 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Oct 2025 | Needham | Initiates | Buy | — |
| 24 June 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 9 May 2025 | Guggenheim | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for GHRS.
This page is one stock. Monday covers all of them.
GHRS appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
GHRS vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, GH Research Plc returned +25.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
GHRS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 3.9×
- EV / EBITDA
- —
Cheaper than 24% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −18.8%
- Return on assets
- −13.0%
- Dividend yield
- —
Higher than 33% of US stocks
Higher than 24% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
GH Research Plc has a market value of $1.2B and an enterprise value of $948.8M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$62.3M.
Free cash flow in the twelve months to 30 June 2026: −$51.8M.
GH Research Plc employs 73 people.
Data provided by Twelve Data
GHRS and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at GHRS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own GH Research Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about GHRS
What is the GHRS stock price forecast for 2026-2027?
The 10 Wall Street analysts covering GH Research Plc have a median 12-month price target of $40, with estimates ranging from $38 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is GHRS stock a buy right now?
Of the 10 analysts covering GH Research Plc, 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks GH Research Plc 62 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank GHRS?
As at 21 Nov 2026, GH Research Plc ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (78 of 100).
Will GHRS stock go up?
No one can know that. What the data says: the median 12-month target from 10 analysts implies +128.2% from the last close, and Ticker Nerd's factor model ranks GH Research Plc 62 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the GHRS stock forecast for 2030?
No analyst covering GH Research Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GHRS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $38 to $55 over the next 12 months.
How has GHRS stock performed over the past year?
GH Research Plc returned +25.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does GH Research Plc do?
GH Research PLC is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders, with an initial emphasis on depression and treatment-resistant depression. Its current pipeline centers on mebufotenin-based therapies, including GH001, an inhalable product candidate being studied for treatment-resistant depression, bipolar II disorder, and postpartum depression, and GH002, an intravenous candidate in early clinical development.
About GH Research Plc.
GH Research PLC is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders, with an initial emphasis on depression and treatment-resistant depression. Its current pipeline centers on mebufotenin-based therapies, including GH001, an inhalable product candidate being studied for treatment-resistant depression, bipolar II disorder, and postpartum depression, and GH002, an intravenous candidate in early clinical development. The company is centered on research and development and works to advance novel therapeutic options for mental health conditions with significant unmet medical need. Based in Dublin, Ireland, GH Research PLC is positioned in the broader healthcare and biotechnology markets as a specialist developer of psychedelic-inspired medicines.
CEO Dr. Theis Terwey M.D. · 73 employees · Ireland · https://www.ghres.com